NEW YORK (GenomeWeb) – Microbiome firms Enterome Bioscience and Second Genome today announced that they each have closed financing rounds worth €14.5 million ($16.5 million) and $42.6 million, respectively.

Paris-based Enterome completed a Series C financing round that it said would provide it with additional financing to develop its pipeline of microbiome-related drugs and diagnostics.

The round was led by existing investors Seventure and Lundbeckfond Ventures, and included new investor Nestlé Health Science. Additional terms of the financing were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.